130.12
5.23 (4.19%)
| 前收盘价格 | 124.89 |
| 收盘价格 | 125.27 |
| 成交量 | 2,197,118 |
| 平均成交量 (3个月) | 2,197,961 |
| 市值 | 17,253,902,336 |
| 价格/销量 (P/S) | 14.79 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 29 Jul 2026 |
| 营业毛利率 | -53.82% |
| 营业利益率 (TTM) | -54.33% |
| 稀释每股收益 (EPS TTM) | -3.39 |
| 季度收入增长率 (YOY) | 20.80% |
| 流动比率 (MRQ) | 4.11 |
| 营业现金流 (OCF TTM) | -272.26 M |
| 杠杆自由现金流 (LFCF TTM) | -67.71 M |
| 资产报酬率 (ROA TTM) | -18.64% |
| 股东权益报酬率 (ROE TTM) | -4,584.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Guardant Health, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | -3.5 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.53% |
| 机构持股比例 | 97.57% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | 133.22 | -1,000 | -133,220 |
| JOYCE MEGHAN V. | - | 127.03 | -10,000 | -1,270,300 |
| KROGNES STEVE E. | - | 133.06 | -9,294 | -1,236,660 |
| SAIA JOHN G. | - | 127.51 | -10,000 | -1,275,100 |
| 累积净数量 | -30,294 | |||
| 累积净值 ($) | -3,915,280 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 130.21 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KROGNES STEVE E. | 董事 | 04 Jun 2026 | 卖 (-) | 9,294 | 133.06 | 1,236,660 |
| JOYCE MEGHAN V. | 董事 | 03 Jun 2026 | 卖 (-) | 10,000 | 127.03 | 1,270,300 |
| JOYCE MEGHAN V. | 董事 | 03 Jun 2026 | 执行期权 | 10,000 | - | - |
| KROGNES STEVE E. | 董事 | 31 May 2026 | 执行期权 | 154 | - | - |
| HIDALGO MEDINA MANUEL | 董事 | 28 May 2026 | 卖 (-) | 1,000 | 133.22 | 133,220 |
| SAIA JOHN G. | 职员 | 27 May 2026 | 卖 (-) | 10,000 | 127.51 | 1,275,100 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合